We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-7.17%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$352M
AUM Growth
-$37.7M
Cap. Flow
+$18.2M
Cap. Flow %
5.16%
Top 10 Hldgs %
83.29%
Holding
25
New
–
Increased
14
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
LBRDK icon
Liberty Broadband Class C
LBRDK
+$5.59M
2
RVMD icon
Revolution Medicines
RVMD
+$1.96M
3
SWTX
SpringWorks Therapeutics
SWTX
+$1.93M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.85M
5
ARGX icon
argenx
ARGX
+$1.54M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$3.29M

Sector Composition

Rank Sector Weight
1 Healthcare 68.83%
2 Communication Services 31.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LBRDK icon
1
Liberty Broadband Class C
LBRDK
$4.43B
$109M 31.04%
1,994,510
+108,250
+6% +$5.59M
RVMD icon
2
Revolution Medicines
RVMD
$39.6B
$28.3M 8.04%
729,464
+52,364
+8% +$1.96M
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$25.8M 7.33%
189,272
+13,600
+8% +$1.85M
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$24M 6.83%
638,352
+45,824
+8% +$1.93M
ARGX icon
5
argenx
ARGX
$53.8B
$23.2M 6.6%
54,028
+4,028
+8% +$1.54M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.82B
$21M 5.96%
132,835
-25,622
-16% -$3.29M
MLTX icon
7
MoonLake Immunotherapeutics
MLTX
$1.64B
$17.1M 4.85%
388,835
+27,919
+8% +$1.18M
ARVN icon
8
Arvinas
ARVN
$517M
$15.3M 4.34%
574,378
+35,278
+7% +$1.12M
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.38B
$14.7M 4.18%
905,384
+64,931
+8% +$1.05M
TVTX icon
10
Travere Therapeutics
TVTX
$5.27B
$14.6M 4.15%
1,776,728
+127,507
+8% +$859K
CYTK icon
11
Cytokinetics
CYTK
$10.9B
$13.9M 3.94%
256,449
+18,403
+8% +$1.11M
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$13.4M 3.82%
542,762
+39,003
+8% +$1.11M
RLAY icon
13
Relay Therapeutics
RLAY
$4.34B
$10.5M 2.97%
1,605,346
+115,176
+8% +$787K
PRTA icon
14
Prothena Corp
PRTA
$453M
$8.95M 2.54%
433,471
+31,071
+8% +$672K
EYPT icon
15
EyePoint Inc
EYPT
$1.12B
$6.15M 1.75%
707,404
+50,804
+8% +$710K
SLDB icon
16
Solid Biosciences
SLDB
$858M
$5.45M 1.55%
961,251
– –
CVIIW
17
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$192K 0.05%
548,000
– –
MNYWW
18
MoneyHero Ltd Warrants
MNYWW
$71.6K 0.02%
895,000
– –
CNDA.WS
19
DELISTED
Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
CNDA.WS
$44.9K 0.01%
408,333
– –
IVCPW
20
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
$39.2K 0.01%
490,000
– –
LSBPW
21
DELISTED
LakeShore Biopharma Warrants
LSBPW
$33.4K 0.01%
489,999
– –
CLDI.WS
22
DELISTED
Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
$27.6K 0.01%
655,200
– –
CDAQW
23
DELISTED
Compass Digital Acquisition Corp. Warrant
CDAQW
$27.5K 0.01%
459,906
– –
GATEW
24
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$26.8K 0.01%
735,000
– –
CLDI icon
25
Calidi Biotherapeutics
CLDI
$2.3M
$25K 0.01%
1,042
– –

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Finepoint Capital held 25 positions worth $352M, down 9.7% from $390M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Finepoint Capital deployed $18.2M of net new capital in Q2 2024, adding to 14 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $3.29M trimmed.

  • Finepoint Capital added most to Liberty Broadband Class C in Q2 2024, an estimated $5.59M increase.
  • Finepoint Capital's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $3.29M.
  • Finepoint Capital's ten largest holdings make up 83% of its $352M portfolio in Q2 2024.
  • Finepoint Capital opened 0 new positions and closed 0 in Q2 2024.
  • Finepoint Capital's portfolio value fell 9.7% quarter-over-quarter to $352M.

Based on Finepoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.